8:15–8:40

Abstract 7005^

Confirmatory open-label, single-arm,   multicenter phase 2 study of the BiTE antibody blinatumomab in patients (pts)   with relapsed/refractory B-precursor acute lymphoblastic leukemia (r/r ALL).

BiTE   antibody blinatumomab在复发/难治性急性前体B淋巴细胞白血病患者（r/ r   ALL）的验证性多中心、开放标签的单臂2期研究。

糜坚青(Jian-Qing Mi)

Abstract   7008

Randomized   comparison of ibrutinib versus ofatumumab in relapsed or refractory (R/R)   chronic lymphocytic leukemia/small lymphocytic lymphoma: Results from the   phase III RESONATE trial.

ibrutinib与ofatumumab在复发或难治性（R/R）慢性淋巴细胞白血病/小淋巴细胞淋巴瘤的随机比较：来自RESONATE Ⅲ期试验的结果。

Abstract 7026

Results of a prospective, randomized,   open-label phase 3 study of ruxolitinib (RUX) in polycythemia vera (PV)   patients resistant to or intolerant of hydroxyurea (HU): the RESPONSE trial.

Ruxolitinib（RUX）在羟基脲耐药或不能耐受的真性红细胞增多症（PV）患者的前瞻性、随机、开放标签的Ⅲ期研究结果：RESPONSE试验。

8:40–8:50

专家评述

Discussion Topic: A   comprehensive overview on molecular targeted therapy for leukemia

讨论主题：白血病分子靶向治疗综述

李建勇(Jian-Yong Li)

8:50–8:55

讨论(Q & A)

马  军(Jun Ma)

王健民(Jian-Min Wang)

李建勇(Jian-Yong Li)

8:55–9:20

Abstract LBA2

Impact on overall survival (OS) with   chemohormonal therapy versus hormonal therapy for hormone sensitive newly   metastatic prostate cancer (mPrCa): An ECOG-led phase III randomized trial.

一项ECOG领导的 III期随机临床试验：激素敏感的新发转移性前列腺癌患者（mPrCa）接受化疗联合内分泌治疗对比单用内分泌治疗对于总生存期(OS)的影响。

戴  波(Bo Dai)

Abstract 5003

Immediate versus deferred initiation of   androgen deprivation therapy in prostate cancer patients with PSA-only   relapse.

PSA复发的前列腺癌患者接受立即雄激素剥夺治疗与延迟雄激素剥夺治疗的比较。

Abstract 5008

Phase 3, randomized, placebo-controlled   trial of orteronel (TAK-700) plus prednisone in patients (pts) with   chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC)   (ELM-PC 4 trial).

三期、随机、安慰剂对照临床试验（ELM-PC 4试验）：orteronel(tak - 700)联合强的松治疗未接受过化疗的转移性去势抵抗型前列腺癌患者（mCRPC）的研究。

9:20–9:30

专家评述

Discussion Topic: Feasibility   of combined therapy for patients with hormone-sensitive prostate cancer

讨论主题：对激素敏感型前列腺癌患者进行联合治疗的可行性

何志嵩(Zhi-Song He)

9:30–9:35

讨论(Q &   A)

叶定伟(Ding-Wei Ye)

马建辉(Jian-Hui Ma)

何志嵩(Zhi-Song He)

9:35–10:00

Abstract 5009

Nivolumab for metastatic renal cell   carcinoma (mRCC): Results of a randomized, dose-ranging phase II trial.

Nivolumab治疗转移性肾细胞癌（mRCC):一项随机的关于剂量调整的II期临床研究结果。

姚  欣(Xin Yao)

Abstract 5011

Inhibition of PD-L1 by   MPDL3280A and clinical activity in pts with metastatic urothelial bladder   cancer (UBC).

MPDL3280A抑制PD-L1及其对转移性膀胱尿路上皮癌患者的临床作用。

Abstract 5012

Immunomodulatory activity of nivolumab in   previously treated and untreated metastatic renal cell carcinoma (mRCC):   Biomarker-based results from a randomized clinical trial.

Nivolumab对经治和未治转移性肾细胞癌的免疫调节活性：基于生物标志物的随机临床试验结果。

10:00–10:10

专家评述

Discussion Topic: Immunotherapy for RCC?

讨论主题：肾癌细胞免疫治疗？

王秀问(Xiu-Wen Wang)

10:10–10:15

讨论(Q &   A)

周芳坚(Fang-Jian Zhou)

谢晓冬(Xiao-Dong Xie)

王秀问(Xiu-Wen Wang)

10:30–10:55

Abstract 9000^

Efficacy and safety of the anti-PD-1   monoclonal antibody MK-3475 in 411 patients (pts) with melanoma (MEL).

抗PD-1单抗（MK-3475）治疗411例黑色素瘤患者的疗效和安全性研究结果。

斯  璐(Lu Si)

Abstract LBA9008

Ipilimumab versus placebo after complete   resection of stage III melanoma: Initial efficacy and safety results from the   EORTC 18071 phase III trial.

Ipillimumab与安慰剂辅助治疗III期黑色素瘤术后患者的III期对照研究（EORTC18071）：初步疗效和安全性结果。

Abstract 9003^

Survival, response duration, and activity   by BRAF mutation (MT) status of nivolumab (NIVO, anti-PD-1, BMS-936558,   ONO-4538) and ipilimumab (IPI) concurrent therapy in advanced melanoma.

抗PD-1单抗nivolumab（BMS-936558）联合Ipilimumab（IPI）治疗不同BRAF基因突变状态的晚期黑色素瘤患者的生存、疗效持续时间和活化情况的影响。

10:55-11:05

专家评述

Discussion Topic: Adjuvant immunotherapy for resectable melanoma?

讨论主题：可手术黑色素瘤的辅助免疫治疗？

张晓实(Xiao-Shi Zhang)

11:05-11:10

讨论(Q &   A)

郭  军(Jun Guo)

梁  军(Jun Liang)

张晓实(Xiao-Shi Zhang)

11:10-11:35

Abstract 4003

Phase III study of apatinib in advanced   gastric cancer: A randomized, double-blind, placebo- controlled trial.

阿帕替尼治疗晚期胃癌的随机、双盲、安慰剂对照的III期临床研究。

张小田(Xiao-Tian   Zhang)

Abstract 4005

RAINBOW: A global, phase III, randomized,   double-blind study of ramucirumab (RAM) plus paclitaxel (PTX) versus placebo   (PL) plus PTX in the treatment of metastatic gastroesophageal junction and   gastric adenocarcinoma (mGC) following disease progression on first-line   platinum- and fluoropyrimidine- containing combination therapy—Efficacy   analysis in Japanese and Western patient.

RAINBOW：一项ramucirumab（RAM）对比安慰剂联合紫杉醇治疗一线铂类／氟尿嘧啶失败的转移性胃食管结合部或胃腺癌的全球随机、双盲、III期研究——日本与西方人群的疗效分析。

Abstract 4008

Phase III trial to compare   capecitabine/cisplatin (XP) versus XP plus concurrent capecitabine-   radiotherapy in gastric cancer (GC): The final report on the ARTIST trial.

卡培他滨／顺铂（XP）对比XP联合卡陪他滨同步放疗治疗胃癌的III期研究：ARTIST的最终结果汇报。

11:35–11:45

专家评述

Discussion Topic: Anti-angiogenesis for gastric cancer

讨论主题：胃癌的抗血管生成治疗

郭伟剑(Wei-Jian   Guo)

11:45–11:50

讨论(Q &   A)

沈  琳(Lin Shen)

徐建明(Jian-Ming Xu)

郭伟剑(Wei-Jian Guo)